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HPV antibodies or DNA and lung cancer survival. In conclusion, we found no supportive evidence for the 15 hypothesized causal association between HPV infections and lung cancer.
Introduction

1
Lung cancer accounts for over a million deaths worldwide each year (1) . Although smoking is the most 2 important risk factor, lung cancer also occurs in never smokers with particularly high rates reported 3 among women in south Asia (2, 3) . Among other known risk factors, a role for human papillomavirus 4 (HPV) infections has been postulated (4).
6
HPV infections cause almost all cervical cancers, nearly half of ano-genital cancers and a substantial 7 proportion of oropharyngeal cancers (5) . Evidence for the association between HPV and lung cancer 8 comes from over 50 case-studies that have examined the presence of HPV-DNA in lung tumor tissues. A 9 recent meta-analysis estimated that nearly 7% (95% CI: 4.7-10.6) of lung cancer is HPV16-associated and 10 almost 6% (95% CI: 3.5-9.0) HPV18-associated (6) . Interpreting these findings is difficult due to the 11 variation in HPV prevalence, both across and within geographic regions. A more recent study did not 12 observe any HPV DNA in nearly 400 lung tumors examined (7) . A recent Taiwanese study, however, 
16
That HPV can reach the lung is well established through the occurrence of respiratory papillomas (9 
10
and active follow-up through study participants and their next of kin. In this analysis, we excluded all 11 prevalent cancers (other than non-melanoma skin cancers), secondary lung cancer cases and subjects 12 lost to follow-up. HPV serology data were available among a similar group of cancer-free cohort 13 members as a part of a parallel head and neck cancer study (19) . Even though controls in the nested 14 case-control study were matched to head and neck cancer cases on country, sex, date of blood collection
15
(1 month, relaxed to 5 months for sets without available controls), and date of birth (1 year, relaxed to 16 5years for sets without available participants), they were processed and analyzed at the same time as the 17 lung cases and under identical conditions. A total of 1449 lung cancer cases and 1599 controls were 18 available from the EPIC study. All three studies were approved by the IARC Ethics Committee and local
19
ethical review boards of the participating centers.
20
HPV serology
21
The three high-risk (HPV16, HPV18 and HPV31) and two low-risk (HPV6 and HPV11) types tested in this viral proteins and cutaneous HPV-types were tested as specificity controls. In total, plasma samples from 1 4328 controls and 3083 lung cancer cases were tested using the bead-based multiplex serology method 2 described elsewhere (20) . Serology data were dichotomized based on study-specific cut-offs derived 3 using a set of known reference sera (21, 22) . Thresholds derived for the prospective study, which were 4 higher in general, were applied to the retrospective studies to allow for comparisons. Serology testing 5 was performed blind to case-control status. (24) . We adopted a stringent definition to call a HPV 5 DNA-positive tumor based on two rounds of HPV genotyping. In the first genotyping round, all cases that 6 passed the independent pathological evaluation were tested (n=290). Subsequently, in order to confirm 
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The association between HPV antibodies and the risk of lung cancer was examined by calculating the 6 odds ratios (OR) and corresponding 95% confidence intervals (95% CI). Unconditional logistic regression 7 models were adjusted for age, sex, smoking status (never, former or current) and country. Further 8 stratified analyses were performed by sex and smoking status (ever, never) to examine any potential 9 effect modification. We used chi-squared tests to examine the heterogeneity in OR by study design. The 
20
Results
21
The retrospective CE study contributed the largest number of participants (n=3321), followed by the EPIC 22 nested case-control study (n=3048). Lung cancer cases were more often men and compared to controls, were more likely to complete lower levels of education, and ever smoke (Table 1) . A schematic 1 representation of the tests performed in the retrospective studies is represented in figure 1.
2
HPV serology and lung cancer associations
3
Retrospective studies
4
Combined results of the retrospective studies are presented (Table 2 ). Since early antibodies are 5 considered markers of HPV-related malignancy, they are expected to be rare. Consistent with this notion, 6 the prevalence of antibodies to early proteins (E6 & E7) was lower among controls compared to cases.
7
When were grouped based on their carcinogenic potential into any high risk, any low risk or any HPV 8 categories, seropositivity to most early and late antibodies was associated with increased risk of lung 9 cancer. Further, some type-specific antibodies were consistently associated with lung cancer, including 10 HPV16-L1, HPV16-E7, HPV18-L1, HPV18-E7, HPV31-E6, HPV6-L1, HPV11-L1, -E6 and -E7. We observed 11 directional consistency in the risk estimates of capsid and early protein antibodies by HPV-type (Table 2) .
12
Irrespective of whether study-specific thresholds, higher cut-off of the two studies, or twice the highest 13 threshold was applied, the association between type-specific antibodies and the lung cancer risk 14 remained consistent (Supplementary table 1) . We observed no effect modification by smoking status,
15
except for HPV31-E7 where a stronger association was observed among never smokers (OR: 6.59, 95% In the analysis of all-cause mortality, 221 cases with serology data were available in the L2 study and 114 8 deaths were recorded (87 from lung cancer). One hundred and twenty three cases were available in the 9 tumor analysis and 62 deaths were recorded. The longest follow-up time was 6.1 years and the median 10 follow-up time was 3.62 years. In the EPIC study, a total of 1423 cases were available and the maximum 11 follow-up time was 14.7 years during which 1203 deaths occurred. We observed no association between 12 the presence of any HPV antibodies or DNA and overall mortality. Individually, neither HPV16 or HPV11 13 antibodies, nor HPV16 or HPV11 DNA were associated with all-cause mortality following lung cancer 14 (Table 5) . Further adjustment for stage at diagnosis did not change the results (data not shown).
Furthermore, none of the markers of HPV infection were associated with cause-specific mortality due to 16 lung cancer (data not shown).
18
Discussion
19
In this study, we found no evidence for a causal association between HPV infection and lung cancer.
20
Based on a stringent definition of HPV DNA-positivity we observed that 9.7% of lung cancers in Europe
21
were positive for any HPV type, 6.6% for HPV16 and 2.4% for HPV11. Though 1.4% (4 of 290) of the lung (27, 28) . Presence of HPV16 E6 antibodies in particular, are thought to be cancer 5 specific markers owing to their rarity among controls (<1% seropositivity in nearly 6500 controls based 6 on studies of head and neck cancer) (29) (30) (31) (32) . Conversely, HPV16 E6 appears to be a specific marker for 7 HPV16-positive oropharyngeal cancer (19) . We applied HPV serology as a test in the retrospective and 8 prospective designs to address independent questions. In the retrospective studies, serological testing 9 was applied as an initial screen to examine the potential associations between type-specific HPV
10
antibodies and lung cancer and also determine whether HPV serology could predict the presence of the 11 corresponding HPV DNA in the tumor. The prospective analysis was conducted to examine the 12 temporality of the association and to determine if antibody markers may be detectable prior to clinically 13 apparent disease, as we recently observed for oropharyngeal cancer (19) . In the interpretation of the 14 serological associations, we considered: (i) the consistency of antibody prevalence across the studies, (ii) 15 directional consistency within a study between capsid and early antibodies by HPV-type, (iii) potential 16 effect modification by smoking status, and (iv) sensitivity of the results to seropositivity thresholds. In 17 this study, the association between type-specific HPV antibodies and lung cancer appeared to differ by 18 study design. It remains possible that the apparent difference by study design could be attributed to 19 false findings or cancer-specific immune changes in the retrospective cases. However, it is important to 20 note that consistently no association was found for HPV16 E6 seropositivity, considered a cancer-specific 21 marker and also the HPV type with the strongest a priori hypothesis. It is important to mention that the 
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This study raises several questions regarding the published associations between HPV and lung cancer. 
10
DNA prevalence reported within the same country, such as the observed range of 0-78% in Japan (33, 34) 11 and 12-55% in China (35, 36) . Second, some of the regional difference in HPV prevalence has been 12 attributed to varying proportions of non-smoking women and lung histologies (37) . In this study, we
13
observed that the proportion of HPV16 DNA-positivity was comparable between smoking men (7%) and 14 non-smoking women (7.5%) as well as across different lung cancer histologies (Supplementary table 3) .
15
Third, this study demonstrates that although nearly 10% of lung tumors may be consistently HPV DNA- 
